Omalizumab Treatment of Systemic Mast Cell Activation Disease: Experiences from Four Cases

Gerhard J. Molderings; Martin Raithel; Felix Kratz; Marc Azemar; Britta Haenisch; Sabrina Harzer; Jürgen Homann

doi:10.2169/internalmedicine.50.4640

CASE REPORTS

Omalizumab Treatment of Systemic Mast Cell Activation Disease: Experiences from Four Cases

Gerhard J. Molderings, Martin Raithel, Felix Kratz, Marc Azemar, Britta Haenisch, Sabrina Harzer, Jürgen Homann

Author information

Keywords: systemic mastocytosis, omalizumab, tryptase

JOURNAL OPEN ACCESS

2011 Volume 50 Issue 6 Pages 611-615

DOI https://doi.org/10.2169/internalmedicine.50.4640

Details

Abstract

We report on the outcome of 4 patients with therapy-resistant systemic mast cell activation disease (MCAD) treated with the anti-IgE monoclonal antibody omalizumab in compassionate use. Two patients achieved an impressive persistent clinical response to treatment with omalizumab. In the third patient symptoms gradually improved. In the fourth patient omalizumab treatment had to be discontinued due to intolerable mast cell mediator-induced symptoms. In conclusion, omalizumab can lessen the intensity of the symptoms of systemic MCAD. Hence, omalizumab should be considered as a therapeutic option in cases of systemic MCAD that are resistant to evidence-based therapy.

Corresponding author

Register with J-STAGE for free!